April 17, 1991

Incorrect Information

JAMA. 1991;265(15):1953. doi:10.1001/jama.1991.03460150057023

This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.


An error occurred in the Medical News & Perspectives article entitled "Controversy Grows Over Monitoring System for New Schizophrenia Drug," published in the November 21 issue of The Journal (1990;264:2488, 2491). On page 2488, the second sentence in the third column should have read as follows: "In England, where clozapine has been in use for several years, WBC testing for patients who are beginning clozapine therapy requires a minimum blood monitoring frequency (operated through a centralized system) of weekly testing for the first 18 weeks (not 'therapy is only mandated every 2 weeks') and then every 2 weeks thereafter (not 'After 18 months, monitoring moves to a monthly basis.')."

View Original Article